JPWO2020173935A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020173935A5 JPWO2020173935A5 JP2021549575A JP2021549575A JPWO2020173935A5 JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5 JP 2021549575 A JP2021549575 A JP 2021549575A JP 2021549575 A JP2021549575 A JP 2021549575A JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19159299 | 2019-02-26 | ||
| EP19159299.7 | 2019-02-26 | ||
| PCT/EP2020/054897 WO2020173935A1 (en) | 2019-02-26 | 2020-02-25 | New isoindolinone substituted indoles and derivatives as ras inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523201A JP2022523201A (ja) | 2022-04-21 |
| JP2022523201A5 JP2022523201A5 (https=) | 2023-03-03 |
| JPWO2020173935A5 true JPWO2020173935A5 (https=) | 2023-03-03 |
| JP7426398B2 JP7426398B2 (ja) | 2024-02-01 |
Family
ID=65598476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549575A Active JP7426398B2 (ja) | 2019-02-26 | 2020-02-25 | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12281099B2 (https=) |
| EP (1) | EP3931188B1 (https=) |
| JP (1) | JP7426398B2 (https=) |
| CN (1) | CN113474340B (https=) |
| WO (1) | WO2020173935A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| AU2021263914A1 (en) | 2020-04-29 | 2022-11-03 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
| EP4313151A1 (en) | 2021-03-31 | 2024-02-07 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| CN115232114B (zh) | 2021-04-23 | 2023-12-19 | 上海领泰生物医药科技有限公司 | Sos1降解剂及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| US20240408064A1 (en) * | 2021-10-15 | 2024-12-12 | Genetolead Inc. | Ras inhibitors, compositions and methods of use thereof |
| TW202334136A (zh) * | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | PI3Kα抑制劑及其製造與使用方法 |
| US12499866B2 (en) | 2021-12-17 | 2025-12-16 | Shure Acquisition Holdings, Inc. | Adaptive acoustic echo cancellation for a stereo audio signal |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| JPWO2024209717A1 (https=) | 2023-04-06 | 2024-10-10 | ||
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682483A1 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| JP6473133B2 (ja) | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| AU2014331794C1 (en) | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| MX388781B (es) | 2015-07-22 | 2025-03-20 | Araxes Pharma Llc | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. |
| EP3365334B1 (en) * | 2015-10-21 | 2024-07-17 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-02-25 WO PCT/EP2020/054897 patent/WO2020173935A1/en not_active Ceased
- 2020-02-25 CN CN202080016480.4A patent/CN113474340B/zh active Active
- 2020-02-25 US US17/430,011 patent/US12281099B2/en active Active
- 2020-02-25 EP EP20707599.5A patent/EP3931188B1/en active Active
- 2020-02-25 JP JP2021549575A patent/JP7426398B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020173935A5 (https=) | ||
| JP2021520345A5 (https=) | ||
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2018528261A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2004514663A5 (https=) | ||
| JPWO2019195124A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JPWO2020243415A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2019529518A5 (https=) | ||
| JP2012530703A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2020530007A5 (https=) | ||
| JPWO2020139988A5 (https=) | ||
| JP2007505044A5 (https=) | ||
| JPWO2020163823A5 (https=) | ||
| JP2006503805A5 (https=) | ||
| CA2321149A1 (en) | Antitumor agents | |
| KR101010871B1 (ko) | 시아노구아니딘 프로드럭 | |
| KR890006228A (ko) | 항종양제로서 폴리아민 유도체 | |
| JPWO2019201283A5 (https=) | ||
| RU2004111787A (ru) | Ретиноидные агонисты (1), производные алкилмочевины | |
| JP2010535203A5 (https=) |